Logo image of SPRY

ARS PHARMACEUTICALS INC (SPRY) Stock Fundamental Analysis

NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD

17.69  -0.29 (-1.61%)

After market: 17.69 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SPRY. SPRY was compared to 560 industry peers in the Biotechnology industry. SPRY has a great financial health rating, but its profitability evaluates not so good. SPRY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SPRY has reported negative net income.
SPRY had a negative operating cash flow in the past year.
In the past 5 years SPRY reported 4 times negative net income.
SPRY had negative operating cash flow in 4 of the past 5 years.
SPRY Yearly Net Income VS EBIT VS OCF VS FCFSPRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

SPRY's Return On Assets of -4.78% is amongst the best of the industry. SPRY outperforms 87.54% of its industry peers.
The Return On Equity of SPRY (-6.83%) is better than 89.15% of its industry peers.
Industry RankSector Rank
ROA -4.78%
ROE -6.83%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
SPRY Yearly ROA, ROE, ROICSPRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

With an excellent Gross Margin value of 90.89%, SPRY belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
SPRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRY Yearly Profit, Operating, Gross MarginsSPRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

8

2. Health

2.1 Basic Checks

SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRY has more shares outstanding
SPRY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRY Yearly Shares OutstandingSPRY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SPRY Yearly Total Debt VS Total AssetsSPRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SPRY has an Altman-Z score of 10.96. This indicates that SPRY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SPRY (10.96) is better than 88.08% of its industry peers.
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.96
ROIC/WACCN/A
WACC9.79%
SPRY Yearly LT Debt VS Equity VS FCFSPRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 11.00 indicates that SPRY has no problem at all paying its short term obligations.
SPRY has a better Current ratio (11.00) than 80.96% of its industry peers.
SPRY has a Quick Ratio of 10.74. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.
SPRY has a Quick ratio of 10.74. This is amongst the best in the industry. SPRY outperforms 80.61% of its industry peers.
Industry RankSector Rank
Current Ratio 11
Quick Ratio 10.74
SPRY Yearly Current Assets VS Current LiabilitesSPRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.46% over the past year.
Looking at the last year, SPRY shows a very strong growth in Revenue. The Revenue has grown by 971120.00%.
EPS 1Y (TTM)63.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
Revenue 1Y (TTM)971120%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SPRY will show a very strong growth in Earnings Per Share. The EPS will grow by 106.56% on average per year.
Based on estimates for the next years, SPRY will show a very strong growth in Revenue. The Revenue will grow by 108.60% on average per year.
EPS Next Y-3102.21%
EPS Next 2Y-292.38%
EPS Next 3Y90.08%
EPS Next 5Y106.56%
Revenue Next Year330.36%
Revenue Next 2Y241.28%
Revenue Next 3Y169.42%
Revenue Next 5Y108.6%

3.3 Evolution

SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRY. In the last year negative earnings were reported.
Also next year SPRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRY Price Earnings VS Forward Price EarningsSPRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRY Per share dataSPRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

SPRY's earnings are expected to grow with 90.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-292.38%
EPS Next 3Y90.08%

More info and screens

0

5. Dividend

5.1 Amount

SPRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (7/11/2025, 8:00:02 PM)

After market: 17.69 0 (0%)

17.69

-0.29 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners72.25%
Inst Owner ChangeN/A
Ins Owners12.07%
Ins Owner Change0%
Market Cap1.74B
Analysts88.33
Price Target32.23 (82.19%)
Short Float %24.05%
Short Ratio11.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)222.08%
Min EPS beat(2)1.02%
Max EPS beat(2)443.14%
EPS beat(4)2
Avg EPS beat(4)100.5%
Min EPS beat(4)-32.93%
Max EPS beat(4)443.14%
EPS beat(8)5
Avg EPS beat(8)58.43%
EPS beat(12)7
Avg EPS beat(12)92.08%
EPS beat(16)9
Avg EPS beat(16)66.26%
Revenue beat(2)2
Avg Revenue beat(2)220.56%
Min Revenue beat(2)4.48%
Max Revenue beat(2)436.64%
Revenue beat(4)3
Avg Revenue beat(4)160.69%
Min Revenue beat(4)-50.98%
Max Revenue beat(4)436.64%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)-8.46%
EPS NY rev (1m)-4.75%
EPS NY rev (3m)-34.77%
Revenue NQ rev (1m)3.69%
Revenue NQ rev (3m)-4.54%
Revenue NY rev (1m)-4.94%
Revenue NY rev (3m)-10.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.89
P/FCF N/A
P/OCF N/A
P/B 7.59
P/tB 7.84
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.99
BVpS2.33
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.78%
ROE -6.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.89%
FCFM N/A
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.08%
Cap/Sales 0.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11
Quick Ratio 10.74
Altman-Z 10.96
F-Score4
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)338.3%
Cap/Depr(5y)266.86%
Cap/Sales(3y)199.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
EPS Next Y-3102.21%
EPS Next 2Y-292.38%
EPS Next 3Y90.08%
EPS Next 5Y106.56%
Revenue 1Y (TTM)971120%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year330.36%
Revenue Next 2Y241.28%
Revenue Next 3Y169.42%
Revenue Next 5Y108.6%
EBIT growth 1Y56.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-119.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A